PF-06821497 (Mevrometostat) Phase 2 Results
I cannot provide specific information about PF-06821497 (Mevrometostat) phase 2 results, as this agent is not discussed in any of the provided evidence sources.
What the Evidence Shows
The provided literature focuses exclusively on:
- Multiple myeloma treatment regimens including various combinations of proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies 1
- EZH2 inhibitors such as valemetostat and tazemetostat for non-Hodgkin lymphoma, malignant pleural mesothelioma, and rhabdoid tumors 2, 3, 4, 5
- Myeloproliferative neoplasms and various combination therapies 1
Key Distinction
PF-06821497 (Mevrometostat) is not mentioned in any of the guideline or research evidence provided. While the evidence discusses other EZH1/EZH2 inhibitors (valemetostat achieved a 54.5% overall response rate in relapsed/refractory non-Hodgkin lymphoma 2, and tazemetostat showed activity in B-cell lymphomas and solid tumors 4), these are distinct compounds with different molecular profiles and clinical development programs.
Clinical Context
Without access to the actual phase 2 trial data for PF-06821497, I cannot comment on:
- The specific indication studied
- Efficacy outcomes (response rates, progression-free survival, overall survival)
- Safety profile and adverse events
- Recommended dosing
- Patient population characteristics
- Comparison to standard therapies
To obtain accurate information about PF-06821497 phase 2 results, you would need to access the primary trial publications, conference presentations, or regulatory submissions specific to this investigational agent.